received lamivudine or entecavir were enrolled. Short term (4 months) survival was 57 evaluated. One hundred and fourteen patients received lamivudine and 53 patients 58 received entecavir. The baseline characteristics were similar for the two groups except 59 that the entecavir group had older age and lower ALT level. Three patients (8.0%) in 60 the entecavir group and 9 patients (7.9%) in the lamivudine group died (P=1.000). If 61 only patients who started antiviral treatment before serum bilirubin level rises to more 62 than 15 mg/dl were included, 3 patients (8.3%) in the entecavir group and 3 patients 63 (3.0%) in the lamivudine group died (P=0.189). If only patients with a HBV DNA 64 greater than 10 5 copies/ml and a bilirubin level lower than 15 mg/dl were included, 5 65 out of 40 patients (12.5%) in the entecavir group died and 1 out of 59 patients (1.7%) 66 in the lamivudine group died. Multivariate analysis found that entecavir treatment was 67 associated with more mortality than lamivudine (P= 0.035). Early entecavir treatment 68 in patients with high viral load is associated with more short-term mortality than 69 on September 12, 2017 by guest http://aac.asm.org/ Downloaded from lamivudine for chronic HBV with severe acute exacerbation. 70 keywords: hepatitis B, acute exacerbation, entecavir, lamivudine
General Hospital (VGHKS13-CT7-13). 141
Results: 142
In patients who fulfilled the inclusion and exclusion criteria, 53 received entecavir 143 (ETV), 114 received lamivudine (LAM). The baseline ASL, bilirubin, prolongation of 144 PT, platelet, albumin, HBV DNA level and HBeAg status were similar for the two 145 groups. Patients in the ETV group were older than those in the LAM group and had a 146 lower level of ALT (Table 1) . Six out of fifty-three patients (11.3%) in the ETV group 147 died and 9 out of 114 patients (7.9%) in the LAM group died. The observed difference 148 in the mortality rate between ETV and LAM group is not statistically significant 149 (P=0.325). All of the causes of deaths in ETV or LAM group were caused by liver 150 failure. If only patients who received antiviral treatment before the bilirubin level rose 151 by more than 15 mg/dl were included, patients in the ETV group were older than 152 on September 12, 2017 by guest http://aac.asm.org/ those in the LAM group and had a lower level of ALT. The baseline AST, bilirubin, 153 prolongation of PT, platelet, albumin, HBV DNA level and HBeAg status were 154 similar for the two groups (Table 2 ). Five out of fifty patients (10%) in the ETV group 155 died and 3 out of 100 patients (3%) in the LAM group died. The observed difference in 156 the mortality rate between ETV and LAM group is not statistically significant (P=0.083 ). 157
In patients with a baseline HBV DNA greater than 10 5 copies/ml who had started 158
anti-viral treatment before the bilirubin level was greater than 15 mg/dl, those in the 159 ETV group were older than those in the LAM group and had a lower level of ALT, but 160 the baseline AST, bilirubin, prolongation of PT, platelet, albumin, HBV DNA level 161
and HBeAg status were similar between the two groups ( with an improved outcome but in patients with a bilirubin level of greater than or 177 equal to 20 mg/dl, lamivudine treatment did not have survival benefit over control 178 group (14) . In this study if we enrolled only patients who received antiviral therapy 179 before bilirubin level rose to more than 15 mg/dl and a HBV DNA level greater than 180 10 5 copies/ml, the LAM treatment group had a mortality rate of 1.7%. The mortality 181 rate for this study is similar to that for the study by Chien et al., who found that no 182 patients who received LAM treatment before the bilirubin level exceeded 20 mg/dl 183 died (13). Previous studies found that ETV has better antiviral efficacy and lower 184 resistance rate than LAM in chronic HBV (16-17). However, a recent non-randomized 185 study from Hong Kong found that ETV treatment was associated with increased 186 short-term mortality compared with LAM treatment in patients with chronic HBV and 187 severe AE (18). Our study demonstrated that early ETV treatment did not result in 188 (14) 218 but this study did not determine the level of viral load at which LAM treatment is 219 beneficial. Previous studies with patients of chronic HBV with SAE did not 220 demonstrate significant benefits for lamivudine treatment. This may be due to these 221 studies used not only stage II and III patients, but also stage IV patients. The only 222 randomized study from India, which found that tenofovir is associated with a better 223 survival rate than control enrolled only patients with a HBV DNA level of greater 224 than 10 5 copies/ml. It is believed that if this study had also used patients with a HBV 225 DNA of less than 10 5 copies/ml, the benefit of tenofovir may probably disappear. This study has some limitations. This is a not a randomized study and the number of 233 cases in the ETV treatment group is relatively small. Further randomized studies are 234 required to determine whether ETV or LAM treatment produces a better treatment 235 outcome for chronic HBV with severe AE. Since general patient care is expected to 236 improve over time, the higher mortality in the more recent cohort receiving entecavir 237 treatment was a negative bias and further supported the result of this study. Besides, 238 patients in the ETV group were older than those in the LAM group but multivariate 239 analysis did not identify age as an independent factor of mortality. In the study by 240 Wong et al., age was also not shown to be significantly associated with the outcome of 241 entecavir or lamivudine treatment in chronic HBV patients with SAE (18). Similarly, 242 in the study by Chien et al., age was also not shown to be associated with the outcome 243 of lamivudine treatment in chronic HBV patients with SAE (13). The difference in the 244 age of the two groups did not explain the inferior outcome of ETV. 245
Conclusions: 246
Early entecavir treatment in patients with high viral load is associated with more 247 short-term mortality than lamivudine in chronic HBV with severe acute exacerbation. 
